EP0874683A1 - Extra-lumenal crossflow plasmapheresis devices - Google Patents
Extra-lumenal crossflow plasmapheresis devicesInfo
- Publication number
- EP0874683A1 EP0874683A1 EP96936859A EP96936859A EP0874683A1 EP 0874683 A1 EP0874683 A1 EP 0874683A1 EP 96936859 A EP96936859 A EP 96936859A EP 96936859 A EP96936859 A EP 96936859A EP 0874683 A1 EP0874683 A1 EP 0874683A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- hollow fiber
- liquid
- blood
- array
- fibers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000002616 plasmapheresis Methods 0.000 title claims description 9
- 239000012510 hollow fiber Substances 0.000 claims abstract description 62
- 239000012528 membrane Substances 0.000 claims abstract description 47
- 210000004369 blood Anatomy 0.000 claims abstract description 42
- 239000008280 blood Substances 0.000 claims abstract description 42
- 239000000835 fiber Substances 0.000 claims abstract description 36
- 239000007788 liquid Substances 0.000 claims description 26
- 239000011148 porous material Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- 210000000601 blood cell Anatomy 0.000 claims description 13
- 210000004027 cell Anatomy 0.000 claims description 7
- 239000011800 void material Substances 0.000 claims description 6
- 238000004626 scanning electron microscopy Methods 0.000 claims description 5
- 239000004695 Polyether sulfone Substances 0.000 claims description 3
- 229920006393 polyether sulfone Polymers 0.000 claims description 3
- 239000004743 Polypropylene Substances 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 229920002301 cellulose acetate Polymers 0.000 claims description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 2
- 229920002492 poly(sulfone) Polymers 0.000 claims description 2
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 2
- -1 polypropylene Polymers 0.000 claims description 2
- 229920001155 polypropylene Polymers 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims 1
- 238000000926 separation method Methods 0.000 abstract description 7
- 238000003491 array Methods 0.000 abstract description 6
- 238000009295 crossflow filtration Methods 0.000 abstract description 4
- 238000001914 filtration Methods 0.000 description 24
- 230000004907 flux Effects 0.000 description 10
- 206010018910 Haemolysis Diseases 0.000 description 7
- 230000008588 hemolysis Effects 0.000 description 7
- 239000002245 particle Substances 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 238000012856 packing Methods 0.000 description 5
- 238000013461 design Methods 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 239000012466 permeate Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000001471 micro-filtration Methods 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 241000331231 Amorphocerini gen. n. 1 DAD-2008 Species 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 239000004831 Hot glue Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005465 channeling Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000009760 functional impairment Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 238000009285 membrane fouling Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000009941 weaving Methods 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D63/00—Apparatus in general for separation processes using semi-permeable membranes
- B01D63/02—Hollow fibre modules
- B01D63/024—Hollow fibre modules with a single potted end
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
- A61M1/3482—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate by filtrating the filtrate using another cross-flow filter, e.g. a membrane filter
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/18—Apparatus therefor
Definitions
- the present invention relates to plasmapheresis, i.e. removal of plasma from blood, which is currently performed in continuous flow centrifugal separators, which separate cells by density; flat-sheet and intra-lumenal hollow fiber membrane devices, which operate by tangential flow microfiltration; and rotating membrane devices, which enhance microfiltration flux by inducing Taylor vortices.
- plasmapheresis i.e. removal of plasma from blood
- flat-sheet and intra-lumenal hollow fiber membrane devices which operate by tangential flow microfiltration
- rotating membrane devices which enhance microfiltration flux by inducing Taylor vortices.
- each of these devices has its own inadequacies due to one or more of complexity, energy demand, inability to function with simple pumps or under gravity flow, required time for plasma separation, require an undesirably large extracorporeal volume, and the like.
- Hollow-fiber membranes have been used for plasmapheresis by means of intra-lumenal flow in which a cell-containing liquid is introduced within the lumens of the hollow fibers and a cell-free liquid passes through the membrane as permeate.
- intra- lumenal flow cell separation devices have been reviewed in the literature: cf. Plasmapheresis : Therapeutic Applications and New Techniques, Nose Y, et al., Raven Press, New York (1983); Kessler S.B., Blood Purif . , 11:150-157 (1993); and U.S. Pat. Nos. 4,243,532, 4,609,461, 4,668,399 and 4,729,829.
- These devices require the use of large amounts of fiber, typically more than 1,000 sq. cm. of fiber area, have high energy demands, and do not usually function under simple gravity flow. Thus benefits from using hollow fiber membranes have been below expectations.
- membranes that were partially skinned with low surface porosity and reduced hy ⁇ draulic permeability. While these membranes can be used effectively to process feedstocks containing rigid, non-deform- able particles, e.g. yeast particles, which cannot enter small membrane pores, they are not suitable for processing whole blood. Attempts to use a module designed for the extra-lumenal process ⁇ ing of yeast particles with human blood were unsuccessful. When tested with blood, the blood exhibited gross hemolysis and under constant flux operation, the transmembrane pressure drop was excessively high due to membrane fouling. The module, with widely spaced fibers and an average packing density of 15-20%, required high extra-lumenal flow rates to achieve acceptably high average wall shear rates. However, the high flow rates resulted in excessively high maximum wall shear rates and shear stresses upon the formed elements of the blood sample. In addition, the membrane had low surface porosity, requiring high transmembrane pressure to achieve adequate fluxes.
- Blood oxygenators effect gas/liquid transfer, i.e. oxygen into blood, while specifically excluding liquid permeation (filtration) into hollow fiber membranes as is the basis of the present invention.
- liquid permeation filtration
- any filtration is precluded by use of hydrophobic hollow fiber membranes having small pores and by operating at liquid-side pressures that are below the intrusion pressure of the membrane.
- the present invention is directed to the production of improved devices using hollow-fiber membrane arrays to perform blood separations. More particularly, the devices are based upon extra-lumenal crossflow filtration wherein blood is introduced extralumenally and caused to flow across an array of microporous hollow fiber membranes.
- the hollow fiber membranes are oriented both with respect to each other and to the flow of the blood so as to minimize red blood cell hemolysis and deposition onto the membranes.
- Fig. IA is a view along the centeriine of a device of this invention showing the hollow fiber array and the flows of blood cells and liquid through it.
- Fig. IB is a cross-sectional view of the device of Fig. IA.
- Fig. 2 is a perspective view of an embodiment of this inven ⁇ tion in which the orientation of four hollow fiber membranes with respect to each other is shown.
- the devices of this invention are useful in separating blood cells from a liquid in which they are suspended. Generally the liquid will be plasma and the cells will be separated from whole blood. Alternatively, a liquid suspension of blood cells may be used.
- the devices operate by flowing the cell suspension over the external surfaces of hollow-fiber membranes in an operation referred to herein as "extra-lumenal crossflow" (XLC) filtration.
- XLC extra-lumenal crossflow
- Crossflow is used herein to refer to flow wherein the net direction of flow crosses the axes of the hollow fibers. Thus the flow is at an angle to the fibers of from greater than 0° up to 90°, preferably about 10° to 90°, and more preferably about 40° to 90°. Crossflow is contrasted with "tangential flow” in which the flow which is only parallel to the direction of the hollow fibers.
- XLC blood filtration can be characterized by a rate-limiting flux.
- the value of the rate-limiting flux is determined principally by a concentration boundary layer of blood cells which accumulate at the membrane surfaces.
- fouling of a membrane is negligible in a properly controlled blood filtration process and the rate- limiting flux tends to be time-independent within the time scale of typical processes. It has been discovered that the value of the limiting flux depends instead upon the hollow fibers, their orientation and packing density within the device, and the direction of flow with respect to the hollow fibers.
- the values of the rate-limiting flux for preferred embodi ⁇ ments of this invention substantially exceed the rate-limiting fluxes achieved by tangential flow intra-lumenal plasmapheresis devices at similar conditions.
- the higher fluxes allow a much smaller device to process the same volume of blood per unit time or allow a device of equal size to process a larger volume of blood per unit time. Smaller devices can benefit the patient or donor by reducing extracorporeal volume and can be made at lower cost. Processing a given volume of blood in less time provides another benefit to patient or donor.
- Suitable hollow fiber membranes useful in XLC blood filtration devices have an area-average surface pore size, as characterized by scanning electron microscopy, of about 8 ⁇ m or less, preferably less than 3 ⁇ m. By porometry or bubble point test, the average pore size should be between about 0.1 and 1 ⁇ m. If no macromolecules are present in the suspending liquid (e.g. after deglycerolization of previously frozen blood) , then the lower limit on membrane pore size only affects the filtration rate. If macromolecules are to be removed with the filtrate (e.g. during donor plasmapheresis) , then a lower limit on average pore size of about 0.1 ⁇ m is applicable.
- the fibers themselves may be isotropic or anisotropic in their morphology.
- the hollow fibers generally have an outside diameter of between about 100 ⁇ m and 1,500 ⁇ m and an inside diameter of about 50 to 1,200 ⁇ m.
- the hollow fibers may be produced from any material which does not adversely affect both the blood cells and the suspending liquid. Suitable such materials are those used in current intra- lumenal blood filtration and include: polysulfone, cellulose acetate, polypropylene, polyvinylidene difluoride, polyether sulfone, polyvinylalcohol, polymethylmethacrylate, and the like.
- the individual hollow fibers are formed into an array which is characterized by (i) a void fraction e, (ii) an overall bed depth H, (iii) transverse and longitudinal fiber spacings S ⁇ and S 2 , and (iv) an angle of off-set from one row to the next as shown in Figure 2.
- the void fraction is between about 0.2 and 0.8, preferably between about 0.4 and 0.6.
- the void fraction corresponds to a fiber packing density of about 20 to 80%, preferrably 40 to 60%.
- the packing density for a perfectly packed hexagonal array of hollow fibers is about 91%.
- Overall bed depth is also an important parameter as it affects both the uniformity of flow across the hollow fiber array and the pressure drop across the array, which, in turn, affects the transmembrane pressure.
- the overall bed depth is about 0.5 to 20 cm, preferably about l to 5 cm. While bed depths outside of this range can be used, they are not recommended.
- the average fiber spacing will be determined by the fiber outside diameter and selected void fraction.
- the uniformity of fiber spacing should be controlled so as to prevent poor flow distribution and channeling.
- S-L is the horizontal distance between two adjacent fibers and S 2 is the vertical distance between two adjacent fibers.
- the average ratio S 1 /S 2 has a value of about 0.5 to 2.0, preferably about 0.8 to 1.5.
- the range of variation of S ⁇ ⁇ and S 2 between each pair of adjacent fibers is preferably limited to + 50% with respect to the average values.
- a the angle of offset between adjacent rows of fibers in regular arrays, is between about 15° and 75°, preferably between about 30° and 60° .
- random fiber arrays may also be used provided that they meet the void fraction and overall bed depth described herein.
- ⁇ P A1 ⁇ W/MAX - ⁇ • A w /A c
- ⁇ w ⁇ the maximum design wall shear rate
- ⁇ the viscosity of the blood
- a w is the total external wetted area of the hollow fibers.
- a c is the total cross-sectional area of the fiber array normal to flow.
- erythrocytes red blood cells
- This effect is a function of membrane pore size, transmembrane pressure and wall shear rate.
- the extent of hemolysis is inversely propor ⁇ tional to wall shear rate W ; thus maximizing the value of ⁇ w is beneficial in avoiding hemolysis.
- the membrane pore size which pertains here is the surface pore size as determined by scanning electon microscopy. For a value of ⁇ w j , ⁇ of 2,000 sec "1 , the value of the critical pressure function ⁇ P TM y ⁇ that will avoid significant hemolysis, according to Fig.
- ⁇ P A must be limited to the smaller of the two values defined by Equations 1 and 2. If P A1 is greater than ⁇ P A2 , then the value of A c can be adjusted such that ⁇ P A1 equals ⁇ P A2 . If ⁇ P A2 is greater than ⁇ P A1 , then ⁇ P TM IN LET can be lowered such that ⁇ P A2 equals P A1 .
- construction of the array can be carried out by any of a number of techniques well known in the art.
- a fabric can be created by knitting or weaving hollow fibers with a filler yarn or monofilament. The fabric can then be cut and stacked or folded to form the desired array.
- An alternate method is to pass fibers through a series of grids, thus forming a three-dimensional array. Double-sided, pressure sensitive tape can be employed to secure fibers relative to each other in the same plane and then to bond layer to layer.
- a particularly preferred method is to use hot melt adhesives applied either as a molten bead or as a monofilament which is subsequently melted.
- the blood flow into the XLC device when used for donor plasmapheresis is generally at a rate of about 50 to 100 cc/mm and the total external surface area of the hollow fibers is less than 500 sq. cm. , preferably less than 300 sq. cm. , and most preferably less than 200 sq. cm.
- a hollow fiber array is constructed from 190 polyether sulfone hollow fiber membranes having an outside diameter of 1,000 ⁇ m, an inside diameter of 600 ⁇ m, a length of 4 cm, an area-average surface pore size of 3 ⁇ m (estimated by scanning electron microscopy) , an average pore size of 0.5 ⁇ m (determined by porometry) , and a surface porosity of 60-70% (estimated by scanning electron microscopy) .
- the total external surface area of the hollow fibers is 240 sq. cm.
- a random array having a width of 2 cm, a depth of 1.5 cm, a packing density of 50%, and an effective fiber length of 4 cm after encapsulation is formed by placing the hollow fibers into a polycarbonate housing. Using a two-component polyurethane, the ends of the array are encapsulated and bonded to the housing. The tips of the hollow fibers at what will be the outlet end of the array are cut off and manifolds attached to form the XLC device shown in Figs. IA and IB.
- the device is tested with a suspension of fresh (less than 24 hours old) , microaggregate-filtered, human whole blood and the blood hematocrit is raised from about 40 to more than 60, i.e. the plasma content has been reduced from 60% to 40%.
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Water Supply & Treatment (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- External Artificial Organs (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US611495P | 1995-10-23 | 1995-10-23 | |
| US6114P | 1995-10-23 | ||
| PCT/US1996/016944 WO1997015380A1 (en) | 1995-10-23 | 1996-10-23 | Extra-lumenal crossflow plasmapheresis devices |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP0874683A1 true EP0874683A1 (en) | 1998-11-04 |
Family
ID=21719386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP96936859A Withdrawn EP0874683A1 (en) | 1995-10-23 | 1996-10-23 | Extra-lumenal crossflow plasmapheresis devices |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US5846427A (en) |
| EP (1) | EP0874683A1 (en) |
| JP (1) | JPH11513909A (en) |
| AU (1) | AU708340B2 (en) |
| WO (1) | WO1997015380A1 (en) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19913416A1 (en) * | 1999-03-25 | 2000-10-05 | Jostra Medizintechnik Ag | Device with at least one membrane in the form of a hollow fiber for filtering liquids |
| DE10106722B4 (en) * | 2001-02-14 | 2008-11-06 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Special hollow fiber membrane module for use in heavily fouled processes and its production |
| DE10250420A1 (en) * | 2002-10-30 | 2004-09-16 | Basf Coatings Ag | Taylor reactor for material conversions |
| US8828226B2 (en) | 2003-03-01 | 2014-09-09 | The Trustees Of Boston University | System for assessing the efficacy of stored red blood cells using microvascular networks |
| US7790039B2 (en) * | 2003-11-24 | 2010-09-07 | Northwest Biotherapeutics, Inc. | Tangential flow filtration devices and methods for stem cell enrichment |
| US8293107B1 (en) * | 2005-10-19 | 2012-10-23 | The United States Of America As Represented By The Secretary Of The Air Force | Fibers with axial capillary slit that enhances adsorption, absorption and separation |
| AU2007273627B2 (en) * | 2006-07-10 | 2010-06-24 | Asahi Kasei Chemicals Corporation | Process for produciton of hollow-fiber membrane bundles |
| EP2620139B1 (en) | 2008-02-27 | 2016-07-20 | Biomet Biologics, LLC | Interleukin-1 receptor antagonist rich solutions |
| US12089589B2 (en) | 2009-10-12 | 2024-09-17 | Hemanext Inc. | Irradiation of red blood cells and anaerobic storage |
| US9199016B2 (en) | 2009-10-12 | 2015-12-01 | New Health Sciences, Inc. | System for extended storage of red blood cells and methods of use |
| US11284616B2 (en) | 2010-05-05 | 2022-03-29 | Hemanext Inc. | Irradiation of red blood cells and anaerobic storage |
| NZ599891A (en) | 2009-10-12 | 2014-06-27 | New Health Sciences Inc | Blood storage bag system and depletion devices with oxygen and carbon dioxide depletion capabilities |
| BR112012008682A2 (en) | 2009-10-12 | 2017-06-20 | New Health Sciences Inc | "Oxygen depletion device, and method for removing oxygen from red blood cells." |
| PT2608816T (en) | 2010-08-25 | 2023-10-12 | Dartmouth College | Method for enhancing red blood cell quality and survival during storage |
| EP3539381B1 (en) | 2010-11-05 | 2023-05-24 | Hemanext Inc. | Irradiation of red blood cells and anaerobic storage |
| US9067004B2 (en) | 2011-03-28 | 2015-06-30 | New Health Sciences, Inc. | Method and system for removing oxygen and carbon dioxide during red cell blood processing using an inert carrier gas and manifold assembly |
| CN103491993B (en) * | 2011-03-31 | 2016-07-06 | 泰尔茂株式会社 | Artificial lung |
| EP3533507B1 (en) | 2011-08-10 | 2022-03-30 | Hemanext Inc. | Integrated leukocyte, oxygen and/or co2 depletion, and plasma separation filter device |
| US10624924B2 (en) | 2012-03-12 | 2020-04-21 | Grifols, S.A. | Method and device for treating blood cholesterol disorders |
| EP3967143B1 (en) | 2013-02-28 | 2025-05-21 | Hemanext Inc. | Gas addition device for blood treatment and corresponding method |
| US9895418B2 (en) | 2013-03-15 | 2018-02-20 | Biomet Biologics, Llc | Treatment of peripheral vascular disease using protein solutions |
| US10208095B2 (en) | 2013-03-15 | 2019-02-19 | Biomet Manufacturing, Llc | Methods for making cytokine compositions from tissues using non-centrifugal methods |
| US9950035B2 (en) | 2013-03-15 | 2018-04-24 | Biomet Biologics, Llc | Methods and non-immunogenic compositions for treating inflammatory disorders |
| US10143725B2 (en) | 2013-03-15 | 2018-12-04 | Biomet Biologics, Llc | Treatment of pain using protein solutions |
| US20140271589A1 (en) | 2013-03-15 | 2014-09-18 | Biomet Biologics, Llc | Treatment of collagen defects using protein solutions |
| US9758806B2 (en) | 2013-03-15 | 2017-09-12 | Biomet Biologics, Llc | Acellular compositions for treating inflammatory disorders |
| US9878011B2 (en) | 2013-03-15 | 2018-01-30 | Biomet Biologics, Llc | Treatment of inflammatory respiratory disease using biological solutions |
| EP3970731B1 (en) | 2015-03-10 | 2025-11-19 | Hemanext Inc. | Oxygen reduction disposable kits, devices and methods of use thereof |
| BR112017022417B1 (en) | 2015-04-23 | 2022-07-19 | Hemanext Inc | BLOOD STORAGE DEVICE FOR STORING OXYGEN DEPLETED BLOOD AND METHOD FOR REDUCING BLOOD OXYGEN SATURATION DURING STORAGE |
| CN114748503B (en) | 2015-05-18 | 2025-09-30 | 希玛奈克斯特股份有限公司 | Method for storing whole blood and composition thereof |
| EP4049677B1 (en) | 2016-05-27 | 2025-12-10 | Hemanext Inc. | Anaerobic blood storage and pathogen inactivation method |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL269380A (en) * | 1960-09-19 | |||
| US3342729A (en) * | 1964-12-09 | 1967-09-19 | Dow Chemical Co | Permeability separatory cell and apparatus and method of using the same |
| FR2236537B1 (en) * | 1973-07-11 | 1977-12-23 | Rhone Poulenc Ind | |
| GB1558370A (en) * | 1975-09-26 | 1979-12-28 | Asahi Chemical Ind | Blood treating apparatus |
| JPS59186603A (en) * | 1983-04-06 | 1984-10-23 | Asahi Medical Kk | Liquid filtration apparatus |
| DE3600527A1 (en) * | 1986-01-10 | 1987-07-16 | Fresenius Ag | FILTER FOR OBTAINING PLASMA OR PLASMA WATER AND METHOD FOR THE PRODUCTION THEREOF |
| JPS6459067A (en) * | 1987-08-31 | 1989-03-06 | Toshiba Corp | Automatic chemical analysis apparatus |
| US4995967A (en) * | 1987-11-06 | 1991-02-26 | Akzo N.V. | Separator for cell-containing liquids |
| JP2755966B2 (en) * | 1988-11-02 | 1998-05-25 | 泉工医科工業株式会社 | Blood processing equipment |
| CA1325175C (en) * | 1989-05-25 | 1993-12-14 | Asahi Medical Co., Ltd. | Compact plasma separator and an apparatus containing the same |
-
1996
- 1996-10-23 EP EP96936859A patent/EP0874683A1/en not_active Withdrawn
- 1996-10-23 JP JP9516731A patent/JPH11513909A/en active Pending
- 1996-10-23 AU AU74678/96A patent/AU708340B2/en not_active Ceased
- 1996-10-23 US US08/735,966 patent/US5846427A/en not_active Expired - Fee Related
- 1996-10-23 WO PCT/US1996/016944 patent/WO1997015380A1/en not_active Ceased
Non-Patent Citations (1)
| Title |
|---|
| PARKER: "Dictionary of Scientific and Technical Terms", 1989, MCGRAW-HILL, NEW-YORK * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU708340B2 (en) | 1999-08-05 |
| US5846427A (en) | 1998-12-08 |
| WO1997015380A1 (en) | 1997-05-01 |
| JPH11513909A (en) | 1999-11-30 |
| AU7467896A (en) | 1997-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5846427A (en) | Extra-lumenal crossflow plasmapheresis devices and method of use thereof | |
| US11369722B2 (en) | Systems and methods for increasing convective clearance of undesired particles in a microfluidic device | |
| EP0112173B1 (en) | Plasmapheresis process | |
| EP0877648B1 (en) | System for filtering medical and biological fluids | |
| TWI675696B (en) | Tangential flow filtration device for perfusion applications | |
| JP2594786B2 (en) | Method for separating plasma from high molecular weight streams into low molecular weight streams | |
| CA2104969A1 (en) | Rectifying dialyzer, membrane and process | |
| JPH11501866A (en) | Filtration cassette and filter with this laminated | |
| EP0083489A2 (en) | Membrane systems for filtration | |
| JP2002306931A (en) | Special hollow fiber membrane module and its manufacture for use in processes severely hindered by adhesion | |
| WO2014003170A1 (en) | Separation membrane element | |
| JPH08295630A (en) | Plasma separation | |
| EP0399083B1 (en) | A compact plasma separator and an apparatus containing the same | |
| EP0702593B1 (en) | Device and method for separating plasma from a blood product | |
| JPS6316147B2 (en) | ||
| CA2235494A1 (en) | Extra-lumenal crossflow plasmapheresis devices | |
| JP4803341B2 (en) | Flat membrane pore diffusion separator | |
| JPH03173824A (en) | Leukocyte separator | |
| JP2007014666A (en) | External perfusion based blood purifier | |
| Sakai et al. | Low-temperature plasma separation by cross-flow filtration with microporous glass membranes | |
| JPH0549877A (en) | Production of composite filter membrane | |
| EP4613363A1 (en) | Separation membrane element | |
| JP6534068B2 (en) | Module for pore diffusion membrane separation to fractionate component molecules in polymer solution | |
| JPH0557149A (en) | Filter system | |
| JP2019135967A (en) | Manufacturing method of cultured cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19980424 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): BE CH DE DK ES FI FR GB IT LI NL SE |
|
| 17Q | First examination report despatched |
Effective date: 19990112 |
|
| GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
| GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
| GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20011120 |